Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Product Approvals
|
Clinical Trials
|
Product Filings
|
Product Safety
|
Preclinical
|
Product Delays
|
Research & Development - Product Delays
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Ark withdraws EU brain cancer filing for Cerepro and starts strategic review
09 March 2010
Ark Therapeutics has withdrawn the EU filing of its brain cancer gene therapy candidate Cerepro (sitimagene ceradenovec), dropping a previous appeal over a negative opinion from the CHMP. It has at the same time initiated a full strategic review of ...
Japanese recommendation moves alogliptin closer to the market
04 March 2010
An advisory committee to Japan's ministry of health, labour and welfare has recommended for approval Takeda 's oral antidiabetic, alogliptin. The positive opinion moves the DPP-4 inhibitor closer to what is likely to be its first market, following ...
Basilea and J&J terminate Zeftera deal after CHMP negative opinion
22 February 2010
The EU's CHMP has refused to endorse the approval of Basilea Pharmaceutica 's intravenous broad-spectrum cephalosporin antibiotic Zeftera (ceftobiprole) for the treatment of complicated skin and skin structure infections. The decision has prompted ...
Complete response letter for GSK/XenoPort's Horizant over cancer concern
22 February 2010
The US FDA has issued GlaxoSmithKline and XenoPort a complete response letter for their non-dopaminergic restless legs syndrome (RLS) therapy, Horizant (gabapentin enacarbil extended-release, previously known as Solzira). Horizant is ...
BIO attacks US proposal from HHS advisory panel for gene patent limits
12 February 2010
A US federal advisory panel has released six recommendations concerning gene patents. Most significantly, the panel advises that Congress exempt gene patents from infringement liability in certain areas, specifically by limiting the ability of ...
 
Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
Market Insight - Power of observation propels comparative effectiveness research into the mainstream
02 March 2010
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
15 June 2009
In escaping the sweltering heat of America's south, Scrip's US reporter Christopher Spillane meets Amgen's chief medical officer, Dr Sean Harper , who coolly explains how the firm plans to negotiate ...
 
Pfizer's fine: a revisit of self-regulation
10 September 2009
The US is a great place to do business. Being an almost free market, the profits are good, but so also are the temptations. So if you can't be bothered to put the money into a clinical trial to find ...
Commentary - EC final report: bark worse than bite?
23 July 2009
On July 8th, 2009, the European Commission reported on its 18-month inquiry into competition in the pharmaceuticals sector. Bill Batchelor of Baker & McKenzie 's Brussels antitrust practice ...
Cancer drugs: getting more for your money – by Karol Sikora
11 May 2009
Cancer treatment is undergoing a revolution, driven by ageing populations, advanced technologies and an increasingly informed society. Health economics considerations and top-up payments are gaining ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm